DRD4
ENSG00000069696
Target class
GPCR
Chromosome
11
Approved drugs
25
Clinical candidates (approved and in development)
27
- Approved drugs
- 25
- Clinical candidates (approved and in development)
- 27
- Chemical probe available
- Yes
- Target name
- DRD4
- Gene name
- Dopamine receptor D4
- Gene symbol
- DRD4
- Protein name
- D(4) dopamine receptor (D(2C) dopamine receptor) (Dopamine D4 receptor)
- Gene biotype
- Protein coding
- Gene family
- Dopamine receptors
- Target class
- GPCR
- Target type
- Human gene
- Tissues expressed in
- 44
- Protein localisation evidence grade
- Uncertain
- Highest tissue expression
- 7.61
- Tissue specificity (Gini)
- 0.383
- Tissue specificity (tau)
- 0.684
- KEGG gene identifiers
- hsa:1815
- Protein interaction confidence
- 0.785688
- Protein interaction partners
- 32
- R-HSA-390651
- R-HSA-418594
- End position
- 640706
- Start position
- 637269
- Chromosome
- 11
- Strand
- Forward
- Cell membrane
- Multi-pass membrane protein .
- Plasma membrane
- PubMed 1319557
- PubMed 16423344
- PubMed 1840645
- PubMed 20100572
- PubMed 27659709
- PubMed 29051383
- PubMed 7512953
- PubMed 7643093
- PubMed 8078498
- PubMed 9003072
- Tissue specificity (tau)
- 0.683882
- Expression inequality (Gini)
- 0.38342
Expression in transcripts per million
- Pituitary
- 7.61
- Brain - Cerebellum
- 6.97
- Ovary
- 6.82
- Testis
- 6.33
- Brain - Cerebellar Hemisphere
- 6.12
Expression in transcripts per million
- Pituitary7.61
- Brain - Cerebellum6.97
- Ovary6.82
- Testis6.33
- Brain - Cerebellar Hemisphere6.12
- Fallopian Tube5.83
- Nerve - Tibial4.4
- Cervix - Ectocervix4.28
- Uterus4.23
- Prostate4.14
- Thyroid3.83
- Cervix - Endocervix3.75
- Bladder3.27
- Esophagus - Gastroesophageal Junction3.12
- Vagina3.11
- Esophagus - Muscularis3.04
- Colon - Sigmoid2.98
- Brain - Cortex2.79
- Brain - Hypothalamus2.62
- Skin - Not Sun Exposed (Suprapubic)2.47
- Brain - Spinal cord (cervical c-1)2.38
- Brain - Nucleus accumbens (basal ganglia)2.31
- Skin - Sun Exposed (Lower leg)2.24
- Artery - Tibial2.12
- Artery - Aorta2.08
And 29 more, listed on the interactive page.
- GO:0006874
- GO:0007195
- GO:0034776
- GO:0043410
- GO:0048149
- GO:0050482
- GO:0050709
- GO:0051586
- GO:0060158
- GO:0005886
- GO:0016020
- GO:0001591
- GO:0004935
- GO:0004952
- GO:0005515
- GO:0017124
- GO:0035240
- GO:0042802
- GO:0051379
- GO:0051380
receptor binding
Studies
- biochemical: NVS_GPCR_hDRD4.4, is one of one assay component(s) measured or calculated from the NVS_GPCR_hDRD4.4 assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.
Biological samples
- cell-free
Evidence source
Related records
Trials (914)
- "Extended" (Alternate Day) Antipsychotic Dosing
- "Olanzapine for Prevention of Chemotherapy Induced Nausea and Vomiting in Children and Adolescents Receiving Highly Emetogenic Chemotherapy (HEC)"
- 12-week Polysomnography Study of Ropinirole Controlled Release for Restless Legs Syndrome
- 15 Month Study for Adults Who Have Been Diagnosed With Schizophrenia and Incarcerated
- 3-Week Study of Asenapine, Olanzapine and Placebo for Treatment of Bipolar Mania (P07008)
- 3-week Study of Asenapine, Olanzapine and Placebo for Treatment of Bipolar Mania (P07009)
- 40 Week Extension Study Of Asenapine and Olanzapine For Bipolar Disorder (A7501007)(COMPLETED)(P05857)
- 5-HTR2A, DRD2,and COMT Genes Polymorphisms and Olanzapine Plasma Concentration in Treatment of Early-onset Schizophrenia
- 5HT3 Antagonism and Auditory Gating in Schizophrenia
- 6-Month Extension Trial of Asenapine With Olanzapine in Negative Symptom Patients Who Completed the Protocol 25543 (25544)(P05777)
- 6-Month Extension Trial of Asenapine With Olanzapine in Negative Symptoms Patients Who Completed the First 6- Month Trial (A7501014)(COMPLETED)(P05772)
- 9 Week Extension Study of Asenapine and Olanzapine in Treatment of Mania (P07007)(COMPLETED)
- A 12-week Study of Pramipexole Extended Release (ER) in Patients With Parkinson's Disease (PD), Followed by a 52-week Long-term Treatment Period
- A 4-week, Randomized, Rater-blinded, Parallel Study to Evaluate Quetiapine in Improving Sleep Quality of Schizophrenia
- A 6 Month Study to Compare the Metabolic Effects of Paliperidone ER and Olanzapine in Patients With Schizophrenia
- A 6 Week Trial to Study the Efficacy and Safety of a Starting Dose 0.25 mg Pramipexole (Mirapex) in Patients With RLS
- A Cardiac Safety Study of an Investigational Drug to See How if Affects the Heart in People With Parkinson's Disease Complicated by Motor Fluctuations "OFF" Episodes
- A Clinical Research Study Evaluating Ropinirole Treatment For Restless Legs Syndrome (RLS)
- A Clinical Research Study Testing Ropinirole Treatment for Restless Legs Syndrome
- A Clinical Study of KDT-3594 in Patients With Early Parkinson's Disease.
Drugs (36)
- Amoxapine Dopamine receptor antagonist
- Apomorphine D2-like dopamine receptor agonist
- Apomorphine hydrochloride D2-like dopamine receptor agonist
- Bromocriptine D2-like dopamine receptor agonist
- Bromocriptine mesylate D2-like dopamine receptor agonist
- Chlorpromazine D2-like dopamine receptor antagonist
- Chlorpromazine hydrochloride D2-like dopamine receptor antagonist
- Clothiapine Dopamine D4 receptor antagonist
- Droperidol D2-like dopamine receptor antagonist
- Ergoloid Dopamine receptor agonist
- Ergoloid mesylates Dopamine receptor agonist
- Haloperidol D2-like dopamine receptor inverse agonist
- Haloperidol decanoate D2-like dopamine receptor inverse agonist
- Haloperidol lactate D2-like dopamine receptor inverse agonist
- Levomepromazine D2-like dopamine receptor antagonist
- Loxapine D2-like dopamine receptor antagonist
- Loxapine hydrochloride D2-like dopamine receptor antagonist
- Loxapine succinate D2-like dopamine receptor antagonist
- Olanzapine D2-like dopamine receptor antagonist
- Olanzapine pamoate D2-like dopamine receptor antagonist